LARIMAR THERAPEUTICS, INC.
Income Statement
| Line Item | Mar 2018 | Dec 2017 | Sep 2017 | Jun 2017 | Mar 2017 | Dec 2016 | Sep 2016 | Jun 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $12.4M | $10.9M | $9.7M | $10.5M | $9.7M | $7.3M | $10.0M | $10.2M |
| SG&A Expense | $3.3M | $2.4M | $3.1M | $3.0M | $3.6M | $3.2M | $4.8M | $4.9M |
| Operating Income | $-15.7M | $-13.4M | $-12.8M | $-13.5M | $-13.3M | $-10.5M | $-14.8M | $-15.1M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | $458.0K | $8.0K | $31.0K | $53.0K | $73.0K | $97.0K | $132.0K | $140.0K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-16.0M | $-13.1M | $-12.6M | $-13.3M | $-13.0M | $-10.4M | $-14.7M | $-15.0M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-0.58 | $-0.48 | $-0.46 | $-0.49 | $-0.48 | $-0.38 | $-0.54 | $-0.55 |
| EPS (Diluted) | $-0.58 | $-0.48 | $-0.46 | $-0.49 | $-0.48 | $-0.38 | $-0.54 | $-0.55 |
| Shares Outstanding (Basic) | 27.6M | 27.5M | 27.5M | 27.4M | 27.4M | 27.3M | 27.3M | 27.3M |
| Shares Outstanding (Diluted) | 27.6M | 27.5M | 27.5M | 27.4M | 27.4M | 27.3M | 27.3M | 27.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |